These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 33916707)
1. Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms? La Salvia A; Espinosa-Olarte P; Riesco-Martinez MDC; Anton-Pascual B; Garcia-Carbonero R Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916707 [TBL] [Abstract][Full Text] [Related]
2. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Xu J Ther Adv Med Oncol; 2021; 13():17588359211042689. PubMed ID: 34484432 [TBL] [Abstract][Full Text] [Related]
3. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
4. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617 [TBL] [Abstract][Full Text] [Related]
5. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266 [TBL] [Abstract][Full Text] [Related]
6. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Pelle' E; Strosberg J J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33202931 [TBL] [Abstract][Full Text] [Related]
10. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy. van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481 [TBL] [Abstract][Full Text] [Related]
12. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Cives M; Soares HP; Strosberg J Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571 [TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Strosberg JR Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009 [TBL] [Abstract][Full Text] [Related]
14. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716 [No Abstract] [Full Text] [Related]
15. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087 [TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy--A literature review. Berardi R; Rinaldi S; Torniai M; Morgese F; Partelli S; Caramanti M; Onofri A; Polenta V; Pagliaretta S; Falconi M; Cascinu S Crit Rev Oncol Hematol; 2016 Feb; 98():264-74. PubMed ID: 26643525 [TBL] [Abstract][Full Text] [Related]
17. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Kjaer A; Knigge U Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100 [TBL] [Abstract][Full Text] [Related]
18. The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. Bodei L; Ćwikla JB; Kidd M; Modlin IM J Thorac Dis; 2017 Nov; 9(Suppl 15):S1511-S1523. PubMed ID: 29201454 [TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. Severi S; Grassi I; Nicolini S; Sansovini M; Bongiovanni A; Paganelli G Onco Targets Ther; 2017; 10():551-557. PubMed ID: 28203088 [TBL] [Abstract][Full Text] [Related]
20. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Halperin DM; Kulke MH; Yao JC Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]